SAG
DNLI icon

SageView Advisory Group’s Denali Therapeutics DNLI Stock Holding History

SageView Advisory Group’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$413 Buy
+25
New +$422 ﹤0.01% 2463

Other funds holding DNLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SageView Advisory Group's DNLI Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Denali Therapeutics (DNLI) in Q4 2025: 25 shares worth $413. The stake represents ﹤0.01% of the portfolio and ranks #2463 among its holdings.

250 funds tracked by Wall St. Rank hold DNLI as of Q4 2025.

  • SageView Advisory Group held 25 shares of Denali Therapeutics worth $413 as of Q4 2025.
  • Denali Therapeutics was a new SageView Advisory Group position in Q4 2025.
  • Denali Therapeutics made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #2463 holding.
  • 250 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.